David Dodd is a recognized leader with experience and expertise in transforming and restructuring public and private companies. During his career, he has overseen the approval of 10+ NDAs, 15+ acquisitions/divestitures, >$2.5 billion in financial transactions and led over $5 billion in incremental enterprise growth. Mr. Dodd joined the GeoVax Board of Directors in March 2010 and was elected Chairman in January 2011. Effective September 2018, he began serving also as the President, CEO. Mr. Dodd has led GeoVax through a significant transformation including recapitalization and up-listing to Nasdaq, followed by the Company acquiring the exclusive worldwide rights to two Phase 2-status products. Mr. Dodd has served on a development committee of the MacArthur Foundation, as an advisor to the First Minister of Scotland, as the Chair of the American Foundation for Suicide Prevention, as a member of the External Advisory Board of the Petit Institute for Bioengineering & Biosciences (GaTech), as Chair of GaBio, as a board member on the Harvard Business School Healthcare Alumni Association and, in leadership roles with numerous additional organizations. Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University and completed the Harvard Business School of Advanced Management Program.